Table 3.
Flow cytometry panel recommendations.
| Panel | Immune subsets | Recommended markers | Optional (immune) | Optional (malignant) |
|---|---|---|---|---|
| A | T cell | CD45, CD45RA, CD3, CD4, CD8, CD5, CD7, CD16/56, CD27, TCRγδ | HLADR, CD38, CD95, CD62L, CD45RO, PD1/CTLA4/TIM3 | TRBC1, CD26 |
| B | B cell | CD45, CD20, CD19, CD10, CD27, CD38, IgD, IgM, CD25, CD22 | CD305, CD185 | kappa, lambda, CD5, CD23 |
| C | Monocyte/MDSC | CD45, CD14, CD16, CD64, CD300e, CD56, HLADR, CD11b, CD33, CD15, Lin | SLAN, CD141, CD45RO | CD34, CD13 |
| D | NK cell | CD7, CD56, CD8, CD94, CD57, CD161, CD16, CD3, KIR3DL1/DL2, CD45RO | DNAM1, NKG2D, NKp30, NKp46, KIR2DL2 | |
| E | T cell subset − 1 | CD3, CD4, CD8, CD19, CD25, CD127, CXCR5, CXCR3, CCR4, CCR6 | CD95, CD28, CCR7 | |
| F | T cell subset − 2 | CD45RA, CD3, CD4, CD25, CD127, CD194 (CCR4), CD95, CD28, CCR7, CD8 | FOXP3, CXCR5, CXCR3, CCR6, CD45RO | |
| G | Dendritic cells | CD45, Lin, CD123, CD88, HLADR, CD5, CD11C, CD141, CD163, CD11B, CD14 | CD1c, CD303, CD11b. CD45RO |
Note: Each panel explores a specific immune subset with a set of core markers and additional extra‐markers to explore their status and function (immune) or known to be dysregulated in the context of cancer (malignant).